This study examined the emetic activity of several staphylococcal enterotoxin type A and B (SEA and SEB, respectively) mutants that had either one or two amino acid residue substitutions. New sea gene mutations were constructed by site-directed mutagenesis; gene products were obtained with glycine residues at position 25, 47, 48, 81, 85, or 86 of mature SEA. Culture supernatants from Staphylococcus aureus RN4220, or derivatives containing either sea or a sea mutation, were analyzed for the ability to stimulate proliferation of murine splenocytes, as determined by incorporation of [3Hlthymidine. Culture supernatants containing SEA-N25G (a SEA mutant with a substitution of glycine for the asparagine residue at position 25), SEA-F47G, or SEA-L48G did not stimulate T-cell proliferation, unlike supernatants containing the other substitution mutants. Purified preparations of SEA-N25G had weak activity and those of SEA-F47G and SEA-L48G had essentially no activity in the T-cell proliferation assay. All mutants except SEA-V85G, which was degraded by monkey stomach lavage fluid in vitro, were tested for emetic activity. SEA-C106A and two SEB mutants, SEB-D9N/N23D and SEB-F44S (previously referred to as BR-257 and BR-358, respectively), whose construction and altered immunological properties have been reported previously, were also tested in the emetic assay. Each mutant was initially administered intragastrically at doses of 75 to 100 ig per animal; if none of the animals responded, the dose was increased four-to fivefold. SEA-F47G, SEA-C106A, and SEB-D9N/N23D were the only mutants that did not induce vomiting at either dose tested; these three mutants had reduced immunological activity.
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However, there was not a perfect correlation between immunological and emetic activities; SEA-L48G and SEB-F44S retained emetic activity, although they had essentially no T-cell-stimulatory activity. These studies suggest that these two activities can be dissociated.
The staphylococcal enterotoxins (SEs) are emetic toxins that cause staphylococcal food poisoning syndrome (4) . Five major serological types of SEs, referred to as A through E (SEA through SEE), have been characterized. The genes encoding each SE type have been cloned, and their nucleotide and derived amino acid sequences have been determined (3, 7, 8, 11, 12, 17, 18, 26, 34, 48) . On the basis of nucleotide sequence comparisons, the genes can be separated into two main groups: one is composed ofsea, sed, and see, and the other includes seb and sec. sea and seb can be considered representatives of each group. The molecular weights of SEA and SEB are 27,100 and 28,336, respectively. SEA and SEB share 34% amino acid sequence identity (6) . The three-dimensional structure of SEB has been reported recently (59) .
The SEs share a number of other activities; they are pyrogenic, suppress immunoglobulin secretion, enhance endotoxic shock, and induce cytokine production (e.g., interleukin-1, tumor necrosis factor, and gamma interferon) and T-cell proliferation (13, 15, 16, 19, 30, 31, 33, 38, 45, 55, 58) . On the basis of their unusually strong yet specific reactivity with T cells, the SEs belong to a family of substances * Corresponding author. t Wisconsin Regional Primate Research Center publication 32-045. referred to as superantigens (reviewed in references 25, 32, 40, and 42) .
Little is known about the relationship between the structure of the SEs and their emetic activity. Analysis of SEC1 fragments derived from trypsin hydrolysis has demonstrated that intravenous administration of the 22-kDa C-terminal tryptic fragment of SEC1 induces diarrhea, but not vomiting, in rhesus and cynomolgus monkeys (56) . It is not known whether vomiting and diarrhea are manifestations of the same SE action. Carboxymethylation of histidine residues of SEA or SEB renders them nonemetic by the intragastric route of challenge (49, 53, 57) . In addition, it has been demonstrated that the native conformation of SEA is required for full emetic activity when SEA is administered intragastrically (27) .
A great deal of work has been directed towards understanding how the structure of the SEs relates to superantigenic activity. Two groups of investigators have analyzed SECi fragments derived from trypsin hydrolysis, with different results; one group found that the 6.5-kDa N-terminal tryptic fragment weakly induces T-cell proliferation, whereas a different group of investigators demonstrated that the 22-kDa C-terminal tryptic fragment induces T-cell proliferation at levels essentially comparable to those induced by native SEC1 (10, 56) . Carboxymethylation of SEB apparently does not affect its T-cell-proliferative activities (1) . The role of the SE's disulfide loop has been examined by both (29) .
A number of studies with either synthetic peptides or recombinant polypeptides have indicated the importance of the N-terminal region of the SEs for T-cell proliferation (14, 20, 47) . Random mutagenesis of seb has identified three N-terminal regions of SEB which are important for induction of T-cell stimulation (35) .
This study is part of our long-term effort to identify residues of the SEs that are required for their emetic activity. Previously we have observed that mutant SEAs with deletions in either the C terminus or the N-terminal third are not as stable as native SEA (24, 27) . This could explain the lack of detectable emetic activity seen in the mutants containing deletions in the C terminus (27) . In an effort to obtain mutant SEs with stabilities similar to that of native SE, we constructed mutants with single-amino-acid substitutions. For this work, we concentrated on residues which are conserved among all SEs. These SEA mutants were examined in the monkey emetic assay and a murine T-cell proliferation assay. In addition, SEA-C106A (a mutant which has the cysteine residue at position 96 changed to alanine [23] ) and SEB-F44S and SEB-D9N/N23D (previously referred to as BR-358 and BR-257, respectively [35] ), whose construction and altered immunological properties have been reported, were tested for the ability to induce emesis. The finding that SEA-L48G and SEB-F44S were emetic despite having little (if any) superantigenic activity demonstrates that these two activities can be separated.
MATERIALS AND METHODS
Bacterial strains, plasmids, bacteriophage, and media. The bacterial strains, plasmids, and phage used in this study are listed in Table 1 . Descriptions of the sea and seb mutations used in this study are given in Table 2 . Escherichia coli and Staphylococcus aureus were propagated as described elsewhere (7) . Culture conditions and media used for the transformation of E. coli and S. aureus have been described previously (27) (2) . Staphylococcal plasmid DNA was prepared by CsCl2-ethidium bromide dye-buoyant density centrifugation (44) . Nucleotide sequences were determined by the dideoxychain termination method (51) . sea mutations were constructed with pMJB263, a pGEM7Zf(+) derivative that contains sea-1364 (24) . This allele contains a number of engineered restriction enzyme sites which are unique to pMJB263 (Fig. LA) . The derived amino acid sequence of sea-1364 is identical to that of wild-type sea. Therefore, SEA-1364 was used as the positive control and will be subsequently referred to as SEA.
Oligonucleotide-directed mutagenesis (37) was performed on an M13mpll derivative that contained the 1-kb HincIIHindIII fragment of sea-1364 in order to construct sea-1369, sea-1370, and sea-1371. The sequences of the oligonucleotides used were 5'321 aaaaaagtagGcttgtat 3' (sea-1369), 5'205 acgatcaaGGtttGcagca 3' (sea-1370), and 5'209 tcaatttGGG cagcatac 3' (sea-1371). The subscript indicates the 5' nucleotide in sea to which the oligonucleotide anneals, and the allele the oligonucleotide was used to create is indicated in parentheses. Lowercase letters are identical to the nucleotides in sea. Uppercase letters in italic type differ from those in sea; these mutations were chosen to result in the desired substitution and/or to facilitate identification of the desired mutation by destroying a restriction enzyme site. Replicative-form DNA isolated from plaques obtained from each type of mutagenesis reaction was digested with HincIl and AccI. The 300-bp HincII-AccI fragments were gel isolated and ligated with HincIl-AccI-digested pMJB263 in order to form full-length mutant SEAs.
The other sea mutations were constructed by cassette mutagenesis, as described previously (27) . The sequences of the oligonucleotide cassettes are depicted in Fig. 1B were then introduced into S. aureus RN4220 by electroporation, as described previously (27) .
Serological assays. Western blot (immunoblot) analysis and gel double-diffusion assays were performed as described previously (27, 50) . Gel double-diffusion-grade SEA and rabbit polyclonal anti-SEA and anti-SEB antisera were obtained from Merlin Bergdoll. The anti-SEA monoclonal antibodies (MAbs) Cl and E8 have been described previously (24) . Normal rabbit serum was purchased from Sigma and was used for identifying non-SEA-related signals in Western blots. To quantify the amount of SEA or mutant SEAs in the culture supernatants, a twofold dilution series of each supernatant was prepared and loaded onto a polyacrylamide gel alongside known concentrations of SEA. The gels were analyzed by Western blotting, with MAb Cl as the primary antibody. The blots were then analyzed with a GS 300 densitometer (Hoefer Scientific Instruments, San Francisco, Calif.).
Stomach lavage fluid degradation assay. Monkey stomach lavage fluid was obtained from rhesus monkeys (Macaca mulatta) by performing a lavage with 15 ml of 0.9% (wt/vol) NaCl (Abbott Laboratories, North Chicago, Ill.) as described previously (27 Purification of SEs. Purification of SEA-N25G, SEA-F47G, SEA-L48G, and SEA (positive control) was accomplished first by removal of the SE from the culture supernatant with Amberlite CG-50, a carboxylic acid resin (52) , and then by immunoaffinity chromatography. To avoid contamination with protein A, the plasmids containing sea-1364, sea-1365, sea-1370, and sea-1371 were first introduced into the protein A-deficient strain ISP2073 (46) by generalized transduction with phage 80oc, as described previously (27) . In each purification, a 1-liter culture of the ISP2073 derivative producing the toxin of interest was grown overnight, and the bacteria were removed by centrifugation. The culture supernatant was adjusted to pH 5.6 and diluted to 5 liters with distilled water. CG-50 (20 g, dry weight) equilibrated previously in 5 mM sodium phosphate, pH 5.6, was then added to the diluted culture supernatant. The CG-50 was slowly stirred for about 2 h at room temperature and then allowed to settle out. The supernatant was decanted, and the slurry was packed into a column (2.7 by 23 cm; Bio-Rad Laboratories, Hercules, Calif.) to a bed height of 15 cm. The column was washed extensively with distilled water, connected to a UA-5 absorbance/fluorescence detector (Isco, Inc., Lincoln, Nebr.), and the toxin was eluted with 0.5 M sodium phosphate (pH 6.2) containing 0.5 M NaCl. The fractions containing SEA were pooled, dialyzed in PBS, and loaded onto a second column packed with CNBr-activated Sepharose 4B which had been coupled previously to MAb Cl. To make this column, MAb Cl had been purified from ascites fluid with the MAbTrap G kit (Pharmacia). Then 18 mg of purified MAb Cl was coupled to 6 g of CNBr-activated Sepharose 4B as described by the manufacturer. The MAb Cl-coupled Sepharose 4B resin was then packed into a column (2.7 by 23 cm; Bio-Rad Laboratories) to a bed height of 5 cm and washed with PBS. The column was stripped with 0.1 M glycine (pH 2.7) before each use, equilibrated with PBS, and connected to the absorbance/fluorescence detector.
The loaded column was washed extensively with PBS. The SEs were then eluted in 0.1 M glycine (pH 2.7) and neutralized with 0.5 M sodium bicarbonate. The SEAcontaining fractions were dialyzed in PBS and concentrated with Centriprep-10 concentrators (Amicon). The amount of SEA or mutant SEA was quantified by determination of the A277, using an extinction coefficient (Ej7"m) of 12.76 (54) . Each toxin preparation was at least 90% pure, as determined by Coomassie brilliant blue staining of sodium dodecyl sulfate-polyacrylamide gels (data not shown), and each preparation was stored frozen.
SEA and SEA-C106A production by E. coli XL-1 derivatives containing pDG13 and pMV2, respectively, and by S. aureus RN4220 derivatives that contained pMJB273 and pMJB275, respectively, as well as their purification, has been described elsewhere (22, 23) . Purified material was lyophilized and stored frozen.
Purification of SEB, SEB-F44S, and SEB-D9N/N23D produced by E. coli XL-1 derivatives was as described before (35) . SEB and the mutant SEBs were quantified by absorbance determinations, and purified materials were stored frozen (35) . RESULTS 3, 5 , 7, 9, 11, 13, and 15 on blot A and lanes 2, 4, and 6 on blots B and C). The samples analyzed on blot A were from RN4220 (Sea-; lane 1) or RN4220 derivatives producing SEA (lanes 2 and 3), SEA-N25G (lanes 4 and 5), SEA-F47G (lanes 6 and 7), SEA-L48G (lanes 8 and 9), SEA-K81G (lanes 10 and 11), SEA-V85G (lanes 12 and 13), and SEA-D86G (lanes 14 and 15). The samples analyzed on blot B were purified SEA (lanes 1 and 2), purified SEA-C106A (lanes 3 and 4), and culture supernatant of the RN4220 derivative producing SEA-D60G/A61-73 (lanes 5 and 6). The samples analyzed on blot C were purified SEB (lanes 1 and 2), purified SEB-F44S (lanes 3 and 4), and purified SEB-D9N/N23D (lanes 5 and 6). Samples on blots B and C were prepared and analyzed at the same time; therefore, degradation of SEA-D60G/ A61-73 by the stomach lavage fluid served as the control for both blots. A mutant SEB that is degraded by monkey stomach lavage fluid has not been identified. The position of the signal corresponding to SEA or SEB is indicated by the dash on the left. The signals due to proteins with molecular weights larger than that of SEA were probably protein A; these signals, unlike those identified as SEA related, were seen in blots reacted only with normal rabbit serum (data not shown).
Examination
of culture supernatants, using polyclonal anti-SEA antiserum (Fig. 2) . Samples from each RN4220 derivative producing a mutant SEA yielded a signal corresponding in size to SEA which was not present in samples of RN4220, the negative control (Fig. 2) .
To determine whether any of the glycine substitutions dramatically altered the conformation of a SEA mutant compared with wild-type SEA, the SEA mutants were examined by the gel double-diffusion assay with polyclonal anti-SEA antiserum and by Western blotting with two anti -FIG. 3 . Western blot analysis of purified SEA and culture supernatants from S. aureus RN4220 or RN4220 derivatives containing sea or a sea mutation. Blot A was reacted with MAb Cl, and blot B was reacted with MAb E8. Lanes 1, 2, and 3 contained 4, 2, and 1 ,ug of purified SEA per ml, respectively. Samples were from RN4220 (lanes 4 and 12, the negative control) or RN4220 derivatives producing SEA (lane 5), SEA-N25G (lane 6), SEA-F47G (lane 7), SEA-L48G (lane 8), SEA-K81G (lane 9), SEA-V85G (lane 10), SEA-D86G (lane 11), or SEA-C106A (lane 13). The samples in lanes 12 and 13 were run on a separate blot. The position of the signal corresponding to wild-type SEA is indicated. The signals corresponding to proteins with molecular weights greater than that of SEA were probably protein A, as they were visible in blots reacted only with normal rabbit serum, unlike those which were SEA related (data not shown).
SEA MAbs. The epitopes for the two MAbs have been partially characterized previously (24) . MAb Cl's epitope is contained within residues 108 through 230. MAb E8 has a conformational epitope, but the residues making up its epitope have not been localized (24) . All of the mutant SEAs reacted with MAb Cl (Fig. 3; Table 3 ). In contrast to the other mutant SEAs, SEA-V85G and SEA-D86G did not react detectably with MAb E8 (Fig. 3; Table 3 ). All SEA mutants formed a line of identity against polyclonal anti-SEA antiserum in the gel double-diffusion assay (data not shown and Table 3 ).
Induction of T-cell proliferation by mutant SEAs. The culture supernatants from the panel of RN4220 derivatives were tested for the ability to induce proliferation of murine splenocytes. The supernatants used were quantified by Western blotting with MAb Cl, as described previously (24) . Each mutant SEA (and wild-type SEA) was in a concentration of at least 8 ,ug/ml, as determined by densitometric analysis. Compared with an equivalent dilution from a culture supernatant of RN4220 (Sea-), the culture supernatants containing SEA, SEA-K81G, SEA-V85G, and SEA-D86G induced a reproducible, statistically significant increase in incorporation of [3H]thymidine (Table 4) (Table  4) . Mutant SEAs that did not induce a significant T-cell response when tested with culture supernatants were purified by immunoaffinity chromatography, using MAb Cl coupled to Sepharose 4B. These purified preparations were tested for the ability to induce T-cell proliferation at 0.5, 0.05, and 0.005 ,ug per well. SEA purified in the same manner (the positive control) induced significant proliferation at all three concentrations (Table 5 ). Purified preparations of SEA-F47G and SEA-L48G did not cause a significant re- sponse in the assay at any concentration tested (Table 5) . A weak but significant response was observed for purified SEA-N25G tested at 0.05 ,ug per well (Table 5) .
Examination of emetic activity of newly constructed mutant SEAs. Before a mutant SEA was tested for emesis, it was screened for resistance to degradation by monkey stomach lavage fluid in vitro (Fig. 2) . Of the mutant SEAs, only SEA-V85G was degraded by monkey stomach lavage fluid. Therefore, SEA-V85G was not tested in the emetic assay.
For the emetic assays, the amount of SEA or a mutant SEA in the culture supernatant was quantified by Western blot analysis with MAb Cl (data not shown). When SEA, SEA-K81G, or SEA-D86G was administered at a dose of 100 ,ug per animal, two of the three test animals in each group vomited (Table 3 ). In the initial assay, only one animal that received 100 ,ug of SEA-L48G vomited; the other two animals did not appear ill. None of three additional animals given 100 ,ug of SEA-L48G showed any signs of illness. Therefore, the dose of SEA-L48G was increased to 500 ,ug per animal; at the higher dose, all three animals experienced emesis (Table 3) . SEA-N25G did not cause emesis at a concentration of 100 p,g per animal. However, one of three animals that received 500 ,ug of SEA-N25G did vomit, and the other two animals looked ill; both had diarrhea and one experienced retching (Table 3) . None of the animals that received SEA-F47G at a dose of 100 or 500 ,ug per animal exhibited any signs of discomfort. As a negative control, three animals each received a concentrated RN4220 culture supernatant equivalent to the amount that would contain 500 ,ug of a mutant SEA. All three animals that received the negative control sample appeared healthy throughout the test period (Table 3) .
Examination of emetic activity of SEA-C106A, SEB-D9N/ N23D, and SEB-F44S. The emetic assays testing mutant SEBs and the initial experiment with SEA-C106A used material produced from E. coli. The Primate Research Center requires that SEs from E. coli be purified for the emetic assay. Positive controls of the homologous SE isolated by the same procedure used to purify the mutant SE were included in the assays. SEA-C106A has been shown previously to be resistant to digestion with trypsin (23). Examination of the emetic and T-cell-stimulatory abilities of the mutant SEs should provide data about whether these two activities are related. If the emetic activity of SEs is not dependent on their ability to stimulate T-cell proliferation, then it should be possible to dissociate these two activities. If the emetic activity of SE is a direct consequence of its ability to stimulate T-cell proliferation, then all mutants defective in T-cell stimulation should be nonemetic. However, a mutant that is fully active in the T-cell proliferation assay in vitro could be nonemetic in vivo because of degradation.
Published data are consistent with the emetic and T-cellproliferative activities of SEs being separate. Independent laboratories have demonstrated that carboxymethylated SEA or SEB is not emetic by an intragastric route of administration (49, 53, 57) . In a separate report, carboxymethylated SEB was shown to induce proliferation of monkey peripheral blood cells (1) . Another line of evidence suggesting that emesis is not due to superantigenic abilities is that careful examination of toxic shock syndrome toxin 1, another bacterial superantigen, has failed to show that it is an emetic toxin by either the intravenous or the intragastric route of administration (5) . It is possible, however, that the inability of toxic shock syndrome toxin 1 to induce vomiting by the intragastric route is due to its sensitivity to pepsin degradation (5). SEA-L48G and SEB-F44S are the first mutant SEs to be described that retained significant emetic activity but had essentially no immunological activity (Tables 3 to 6 ) (35) . The emetic activity of SEA-L48G was not grossly different from that of wild-type SEA (Table 3) . However, SEA-L48G did not induce T-cell proliferation of murine splenocytes, even at a concentration 100-fold greater than that required to see stimulation by wild-type SEA (Tables 4 and 5 ). Compared with wild-type SEB, the ability of the mutant SEB-F44S to bind to human DR-1-bearing cells and to stimulate interleukin-2 production by several VP-bearing T-cell lines is reduced at least 1,000-and 100-fold, respectively (35) . These decreases did not correlate with the decreased emetic activity of SEB-F44S; although SEB-F44S did not induce emesis at 75 ,ug per animal, it did so when administered at a fourfold-higher dose. These results demonstrate that these immunological assays cannot be used to identify nonemetic SEs.
Several mutant SEs had reduced abilities to induce emesis and either murine T-cell proliferation or interleukin-2 production by T-cell hybridomas. In particular, SEB-D9N/ N23D, SEA-C106A, and SEA-F47G did not induce emesis in any of the animals tested. SEB-D9N/N23D does not induce interleukin-2 expression (35) , and SEA-C106A and SEA-F47G do not induce murine T-cell proliferation (23) (Tables  4 and 5 ). If emesis does not depend on T-cell proliferation, mutant SEs defective in both activation of T-cell proliferation and emetic activity could arise as a result of a residue being critical for two different activities.
If there is a correlation between human and monkey systems, our data are consistent with the conclusion that MHC class II binding is not sufficient for emesis. SEA-C106A and SEB-D9N/N23D bind well to human HLA-DR1, but neither induced emesis at the doses tested. Alternatively, SEB-F44S, which has a 1,000-fold reduction in MHC class II binding, was emetic at 300 ,ug per animal, implying that binding to MHC class II by itself does not invoke the emetic response.
There were two pairs of SEA-SEB mutants that had substitutions at corresponding residues. For one pair, there was a difference in emetic activities. SEB-F44S caused emesis at 300 ,ug per animal, in contrast to SEA-F47G (position 47 of SEA corresponds to position 44 of SEB [9] ), which did not induce a response at 500 ,ug per animal. Perhaps the difference in emetic activities of these two mutants was due to the differences in their substitutions. For the other pair (SEB-D9N/N23D and SEA-N25G; position 25 of SEA corresponds to position 23 of SEB [9] ), it is not clear whether there is a difference in their emetic activities.
SEB-D9N/N23D did not cause emesis at 375 pg per animal, whereas SEA-N25G did cause emesis at 500 pg per animal. SEB-D9N/N23D may have a lower emetic activity than SEA-N25G because of its additional mutation at position 9. Alternatively, SEB-D9N/N23D might be emetic at a dose of 500 ,ug per animal. We did not administer a higher dose of SEB-D9N/N23D, as the three test animals that received doses of 300 ,ug appeared very ill, even though there was no evidence of gastrointestinal upset (e.g., vomiting, diarrhea, or retching). It was not clear whether these nongastrointestinal symptoms were due to SEB-D9N/N23D or to a contaminating substance from E. coli that copurified with the mutant SEB.
